Has Andrew Teklinski, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,117 in general payments to Andrew Teklinski, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Andrew Teklinski, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Andrew Teklinski, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Andrew Teklinski, MD

Cardiovascular Disease · Petoskey, MINPI 1336160555

Payments from drug & device makers

What this record shows

Medtronic accounts for 74.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $777 and has fallen 99.3% since, to $6 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.

$1,117in general payments, 2019–2025

Across 14 payments — averaging $79.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$831
Cardiovascular Systems Inc.$111
Tactile Systems Technology Inc$81
Bard Peripheral Vascular, Inc.$60
Lantheus Medical Imaging, Inc.$29
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$6

$419,914in research payments, 2019–2025

Across 19 payments — averaging $22,101 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$233K
Novartis$186K

What the payments were for

Travel & lodging$55249%
Food & beverage$56551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	8	$831
Cardiovascular Systems Inc.	2	$111
Tactile Systems Technology Inc	1	$81
Bard Peripheral Vascular, Inc.	1	$60
Lantheus Medical Imaging, Inc.	1	$29
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VenaSeal$681

How this compares

$1,117 in reported general payments places this provider in the 35th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan →

Medicare billing

Part B allowed, 2024

$110,303

Medicare patients

1,108

Services billed

1,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	327	$370,791
Repatha SureclickEvolocumab	91	$88,912
EntrestoSacubitril/Valsartan	49	$67,244
XareltoRivaroxaban	44	$59,457
Praluent PenAlirocumab	19	$20,838
Repatha SyringeEvolocumab	15	$20,487
JardianceEmpagliflozin	19	$17,446
NexletolBempedoic Acid	11	$12,252
Metoprolol Succinate	321	$7,369
Atorvastatin Calcium	406	$7,271
Ezetimibe	214	$5,822
Bumetanide	93	$3,989
Rosuvastatin Calcium	171	$3,753
Diltiazem 24hr Er (Cd)Diltiazem Hcl	65	$2,992
Losartan Potassium	196	$2,544

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Petoskey

Marschall RungeAnn Arbor$1.8M
Jihad MustaphaGrand Rapids$1.6M
Vallerie McLaughlinAnn Arbor$947K
Pedro Villablanca SpinettoDetroit$620K
Stanley ChetcutiAnn Arbor$573K
David HainesRoyal Oak$492K
Steven AlmanyTroy$471K
David StroblLansing$445K
Herman KadoSouthfield$442K
Douglas HorstmanshofRoyal Oak$407K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →